This document is a patent application (US20260085118A1) filed with the USPTO, detailing a novel conjugate of an anti-CTLA-4 antibody that is activated by the tumor microenvironment. The conjugate, described by the structure R1-R2-R3-L-R4-S-cys-R5, aims to enhance the targeting capabilities of anti-CTLA-4 antibodies while mitigating drug resistance and reducing overall toxicity.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signifies potential future developments in cancer therapeutics. Companies involved in drug development, particularly in oncology and immunotherapy, should monitor the progress of this patent application and related intellectual property as it may impact their research and development strategies or competitive landscape.